阿托伐他汀治疗心肌梗死后无症状心衰的疗效观察

Curative Effect Observation of Atorvastatin in Treatment of Silent Heart Failure After Myocardial Infarction

目的观察阿托伐他汀在心肌梗死后无症状心衰(SHF)患者中的应用价值。方法将60例符合条件的无症状心衰患者随机分为观察组(31例)和对照组(29例),对照组予以常规治疗,观察组在常规治疗的基础上口服阿托伐他汀钙片。对比两组患者治疗前后左心室射血分数(LVEF)、左心室收缩末期内径(LVESD)、左心室舒张末期内径(LVEDD)、氨基末端脑钠肽前体(NT-pro BNP)水平、6分钟步行试验(6MWT)的结果以及不良反应发生率。结果治疗前,两组LVEF、LVESD、LVEDD等指标相比差异不显著(P>0.05);治疗后,两组以上指标均有所改善,且观察组LVEF显著高于对照组,LVESD和LVEDD均显著低于对照组,差异有统计学意义(P<0.05)。治疗后,两组NT-pro BNP和6MWT指标均有所改善,且观察组NT-pro BNP显著低于对照组,6MWT显著高于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率(6.5%vs 6.9%)相比差异无统计学意义(P>0.05)。结论应用阿托伐他汀治疗心肌梗死后无症状心衰患者可显著改善患者心肌功能,改善预后,安全性高,值得借鉴。

Objective To observe the application value of atorvastatin in patients with silent heart failure （SHF） after myocardial infarction. Methods 60 eligible patients with silent heart failure were randomly divided into observation group （31 cases） and control group （29 cases）. The control group was given conventional treatment, the observation group was given atorvastatin on the basis of the control group. The left ventricular ejection fraction （LVEF）, left ventricular end systolic diameter （LVESD）, left ventricular end diastolic diameter （LVEDD）, NT-proBNP, 6-minute walk test （6MWT） and incidence of adverse reactions before and after treatment in the two groups were compared. Results LVEF, LVESD and LVEDD of the two groups before treatment had no significant difference （P〉0.05）;after treatment, the above indicators of the two groups were improved, and LVEF of the observation group was higher than that of the control group, LVESD and LVEDD were lower than those of the control group, the difference was statistical （P〈0.05）. After treatment, NT-proBNP and 6MWT of the two groups were improved, and NT-proBNP of the observation group was lower than that of the control group, 6MWT was higher than that of the control group, with statistical difference （P〈0.05）. The adverse reactions rate of the two groups had no statistical difference （6.5%vs 6.9%, P〉0.05）. Conclusions Atorvastatin can effectively improve the myocardial function and prognosis of patients in treating patients with silent heart failure after myocardial infarction, which has high safety and deserves reference.